John Hood, Endeavor Biomedicines CEO
‘We’re not that company’: John Hood is building a biotech the old-fashioned way — and not just because he has to now
Even before the biotech boom on Wall Street went bust, John Hood had planned to build his new company using the old business model: lean staff, low overhead, raising cash from committed venture investors rather than generalists on the market, waiting for human data before any M&A or IPO.
So now, after raising $62 million to launch, Hood is back with a $101 million megaround for San Diego-based Endeavor Biomedicines — and no plans to go public.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
